{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-140152","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2026-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.046821+00:00","generated_at":"2026-05-15T07:48:12.456102+00:00","sec_items":["1.01","5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cardiff Oncology finalizes separation agreements with ex-CEO and ex-CFO","bullets":["Dr. Erlander to receive $635k salary over 12 months, $122k 2025 bonus, and 50% of 2026 target bonus pro-rated.","Mr. Levine to receive $490k salary over 12 months, $61.7k 2025 bonus, and 50% of 2026 target bonus pro-rated.","Erlander signs consulting agreement; stock options vest through June 2026, then exercisable for 12 months.","Levine's vested options exercisable for 12 months after separation date.","Erlander resigns from board of directors effective March 27, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-140152","json":"https://secwatch.observer/filing/0001193125-26-140152.json","markdown":"https://secwatch.observer/filing/0001193125-26-140152.md","text":"https://secwatch.observer/filing/0001193125-26-140152.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000119312526140152/0001193125-26-140152-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000119312526140152/crdf-20260327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:48:12.456102+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}